Infiltrating bladder urothelial carcinoma

This early-stage trial tests a personalized cancer vaccine for people with bladder or stomach cancer who still have tiny amounts of cancer DNA in their blood after surgery. The vaccine is made from unique proteins in each person's tumor and aims to train the immune system to find…

This large trial is testing whether a blood test that looks for tumor DNA can help decide who needs immunotherapy after surgery for muscle-invasive urothelial cancer. About 992 participants will be assigned to different treatment plans based on their blood test results. The goal …

This phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …

This early-phase trial tests a combination of three drugs—enfortumab vedotin, pembrolizumab, and quemliclustat—in people with advanced bladder or urinary tract cancer that has spread or cannot be removed by surgery. The goal is to see if the combination is safe and effective. The…

This study tests whether giving two drugs (enfortumab vedotin and pembrolizumab) before bladder cancer surgery can eliminate cancer in the lymph nodes and shrink tumors. About 23 adults with advanced bladder cancer that has spread to lymph nodes will receive the combination befor…

This study tests a combination of the drug enfortumab vedotin and radiation therapy given before surgery for muscle-invasive bladder cancer. It is for patients who cannot receive standard cisplatin chemotherapy. The trial will test three different schedules of the drug and radiat…

This study tests whether two drugs, enfortumab vedotin and pembrolizumab, can control muscle-invasive bladder cancer without needing to remove the bladder. About 390 adults whose cancer hasn't spread outside the bladder will receive either the drug combo or standard chemoradiatio…

This phase II trial is testing whether giving the immunotherapy drug pembrolizumab along with radiation therapy after chemotherapy can help patients with muscle invasive bladder cancer avoid bladder removal surgery. About 111 participants who responded well to initial chemotherap…

This phase III trial tests whether combining two drugs—pembrolizumab (an immunotherapy) and sacituzumab govitecan (a targeted chemotherapy)—works better than standard chemotherapy for people with advanced bladder cancer that has stopped responding to initial immunotherapy. About …

This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…

This phase 2 trial tests whether a combination of enfortumab vedotin and pembrolizumab can help people with muscle-invasive bladder cancer avoid bladder removal. About 240 adults who are candidates for surgery will receive the drugs intravenously. The main goals are to see how ma…

This early-phase trial tests whether adding radiation therapy or bladder removal surgery can safely eliminate remaining cancer in patients with advanced bladder cancer who have already responded to a drug combination. The study enrolls 12 adults with muscle-invasive bladder cance…

This early-stage trial is testing a new oral drug called LOXO-435, alone or with other cancer medicines, in people with advanced solid tumors that have a specific change in the FGFR3 gene. The study aims to find the right dose and check for safety and early signs of effectiveness…

This study compares two radiation schedules for people with muscle-invasive bladder cancer who also receive chemotherapy. One group gets the usual number of radiation treatments, while the other gets fewer, higher-dose sessions. The goal is to see if the shorter course works just…

This early-stage study tests a new drug called 2141-V11 in people with a type of bladder cancer that hasn't responded to standard therapy. The drug is given directly into the bladder through a catheter or by injection into the tumor. The main goal is to see if it's safe and to fi…

This phase 2 trial is testing whether giving chemotherapy before surgery to remove the bladder improves outcomes for people with a specific type of muscle-invasive bladder cancer called luminal subtype. Half the participants will receive standard neoadjuvant chemotherapy followed…

This study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…

This study is for people with muscle-invasive bladder cancer that has not spread. It tests whether removing only the part of the bladder with cancer (partial cystectomy) plus nearby lymph nodes works as well as removing the whole bladder. Participants get standard chemotherapy be…

This study tests a treatment plan for people with a rare, aggressive type of bladder cancer (variant histology) that has grown into the muscle layer. The goal is to see if giving chemotherapy (with or without immunotherapy) followed by radiation and low-dose chemo can save the bl…

This phase 2 trial tests two drugs, enfortumab vedotin and pembrolizumab, in 47 people with muscle-invasive bladder cancer. The goal is to see if the combination can eliminate the cancer so patients can keep their bladder instead of having it surgically removed. After three cycle…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder cancer surgery is safe and effective. About 150 people with muscle-invasive bladder cancer will receive durvalumab plus either ddMVAC or gemcitabine/cisplatin chemo…

This early-phase study tests a combination of two drugs—romidepsin and durvalumab—given directly into the bladder for people with muscle-invasive bladder cancer who cannot receive standard chemotherapy. The goal is to see if the combination is safe and can shrink or eliminate tum…

This phase 3 trial is testing whether a combination of two drugs—datopotamab deruxtecan and rilvegostomig—given after surgery can prevent cancer recurrence in people with high-risk muscle invasive bladder cancer. Participants who have had their tumor completely removed will recei…

This phase 2 trial tests whether adding one of four different drugs to a standard immunotherapy combination can help people with HER2-positive muscle-invasive bladder cancer avoid bladder removal. Participants receive disitamab vedotin and toripalimab plus a sensitizing agent, th…

This early-phase trial tests whether combining the drug sacituzumab govitecan with advanced radiation therapy is safe and tolerable for people with muscle-invasive bladder cancer that hasn't spread. The goal is to treat the cancer while preserving the bladder, avoiding surgical r…

This clinical trial is testing whether a combination of two drugs, SHR-A2102 and adebrelimab, works better than standard chemotherapy for people with muscle-invasive bladder cancer. The treatment is given before and after surgery to remove the bladder. The study involves 840 part…

This phase 3 trial tests whether combining the targeted drug disitamab vedotin (RC48) with chemotherapy (gemcitabine) before surgery works as well as RC48 plus an immunotherapy (toripalimab) for people with HER2-positive muscle-invasive bladder cancer. Participants receive one of…

This early-phase trial is testing whether combining the drug enfortumab vedotin with radiation therapy can help control locally advanced bladder cancer. About 41 adults with urothelial carcinoma of the bladder will receive the drug by IV along with radiation. The main goal is to …

This study tests whether a new combination of drugs (enfortumab vedotin plus toripalimab) works better than standard chemotherapy before bladder cancer surgery. About 58 adults with high-risk muscle-invasive bladder cancer will be randomly assigned to one of the two treatments fo…

This phase II trial is testing the drug pemetrexed in people with advanced bladder cancer or other solid tumors that have spread and carry certain gene mutations (MLL4, UTX, or MTAP). The goal is to see if pemetrexed can shrink tumors. About 64 participants will receive the drug …

This phase III trial tests whether adding local radiotherapy to standard care helps bladder cancer patients who are not eligible for curative treatment live longer and feel better. About 248 participants will be randomly assigned to receive either standard care alone or standard …

This study tests whether a procedure that filters a patient's blood (therapeutic plasma exchange) can help standard cancer drugs work better in people with advanced bladder or urinary tract cancer that has stopped responding to previous treatments. About 70 adults will be randoml…

This early-phase trial is testing whether a combination of two drugs, atezolizumab and tiragolumab, can help control bladder cancer when given before surgery to remove the bladder and tumor. The study includes 10 adults with muscle-invasive bladder cancer who cannot take standard…

This phase 2 trial tests whether combining two drugs—sacituzumab govitecan and nivolumab—after surgery can keep high-risk bladder cancer from coming back. About 23 adults who had their bladder or part of their urinary tract removed will receive the drugs intravenously. The main g…

This early-phase trial is testing whether combining two drugs—cabozantinib and enfortumab vedotin—can safely treat advanced bladder cancer that has spread. About 32 adults whose cancer worsened after standard treatments will receive the combo. The study aims to find the best dose…

This study looks at whether a thorough health check (comprehensive geriatric assessment) before bladder cancer surgery can help older, frail patients recover faster. About 140 people aged 65 and older will be enrolled. The goal is to see if personalized care plans reduce complica…

This study tests a new treatment for muscle-invasive bladder cancer that aims to save the bladder. It combines two drugs (enfortumab vedotin and pembrolizumab) with targeted radiation. About 47 adults with this cancer will receive the therapy to see if it can shrink tumors and av…

This study tests whether giving a targeted drug (enfortumab vedotin) plus an immunotherapy (pembrolizumab) before surgery to remove part or all of the bladder can improve outcomes for people with advanced bladder or urinary tract cancer. About 75 adults with cancer that has sprea…

This study tests whether growing a patient's tumor cells in the lab (organoids) can help doctors choose the most effective chemotherapy after bladder cancer surgery. Researchers will compare survival rates of patients whose chemo was guided by organoid tests versus standard care.…

This early-stage trial tests a modified virus called KD01, given directly into the bladder, to see if it is safe and can fight bladder cancer. The study includes 29 patients with either high-risk non-muscle-invasive bladder cancer or muscle-invasive bladder cancer. Some patients …

This study tests whether a combination of two targeted drugs (zanidatamab and tislelizumab) plus chemotherapy can shrink HER2-positive muscle-invasive bladder cancer enough to avoid bladder removal. About 25 adults with stage T2-T4a bladder cancer will receive the treatment befor…

This phase 2 trial tests erdafitinib alone or with cetrelimab before surgery in 90 people with muscle-invasive bladder cancer that has specific gene changes (FGFR). Participants cannot take standard cisplatin chemotherapy. The goal is to see if the drugs can eliminate or shrink t…

This study tests two drugs, futibatinib and durvalumab, given before surgery to remove the bladder in people with muscle-invasive bladder cancer who cannot take standard chemotherapy. The goal is to see if this combination can eliminate or shrink the cancer enough to improve outc…

This study looks at whether giving patients IV fluids at home for four weeks after bladder cancer surgery can lower the chance of needing to go back to the hospital. About 130 adults having this surgery will be randomly assigned to either get the usual care or the usual care plus…

This study tests whether adding focused radiation to standard treatment helps people with metastatic bladder cancer live longer. It includes patients whose cancer has not worsened after initial therapy and who have three or fewer remaining tumors. About 130 participants will be r…

This study looks at whether it is safe to skip preventive antibiotics after bladder removal surgery for muscle-invasive bladder cancer. Half of the 120 participants will take nitrofurantoin daily for 10–21 days after surgery, while the other half will receive no antibiotics. The …

This phase 2 trial tests whether adding an experimental drug (fianlimab) to standard chemotherapy plus immunotherapy can help people with muscle-invasive bladder cancer avoid bladder removal. About 36 adults will receive either the standard combo or the standard plus fianlimab. T…

This study tests whether a specialized PET/CT scan using a radioactive tracer can more accurately determine the extent of muscle-invasive bladder cancer compared to standard CT scans. It will also explore whether changes seen on a follow-up scan after two cycles of chemotherapy c…

This study compares three imaging methods—FAPI PET/MRI, FDG PET/MRI, and MRI—to see which best detects muscle-invasive bladder cancer and tracks how well pre-surgery treatment works. Researchers will enroll 80 participants with suspected or confirmed bladder cancer. The goal is t…

This study compares CT and MRI scans to see which more accurately determines if bladder cancer has spread into the muscle layer. About 150 adults with newly diagnosed bladder cancer will receive both scans before standard surgery. The results will be checked against tissue sample…

This study is testing whether a special MRI scan (mpMRI) can accurately diagnose muscle-invasive bladder cancer without needing an invasive biopsy (TURBT). Researchers will compare the MRI results to the biopsy results in 30 adults with suspected muscle-invasive bladder cancer. I…

This study is testing a new urine test that might find returning bladder cancer earlier and more accurately than current urine tests. The goal is to see if this test can reduce the need for cystoscopy, a procedure where a tiny camera is inserted into the bladder. About 300 adults…

This study compares a new diagnostic approach—using an MRI plus a same-day biopsy—against the standard procedure (TURBT) for diagnosing muscle-invasive bladder cancer. Researchers will enroll 360 adults suspected of having this aggressive cancer. The goal is to see if the new met…

This early-phase study tests a new MRI technique that uses two contrast agents (gadobutrol and ferumoxytol) placed directly into the bladder to improve staging of bladder cancer. Researchers will compare MRI images to actual tumor samples from surgery to see if the scan can accur…

This study looks at whether taking PET scans later (2.5 hours after injection) finds lymph node spread in muscle-invasive bladder cancer more accurately than standard scans (1 hour after). About 66 adults with this cancer will get both scans, and results will be compared to surgi…

This study is testing whether a combined blood and urine DNA test can accurately detect muscle-invasive bladder cancer in patients scheduled for bladder removal surgery. Researchers will compare the test results with the actual findings from surgery. The goal is to see if this no…

This study tests whether a special type of MRI (multiparametric MRI) can predict early on if chemotherapy is working for muscle-invasive bladder cancer. 39 participants will get three MRI scans: before chemo, one day after the first dose, and after finishing chemo. The goal is to…

This study looks at whether walking 8,000 to 10,000 steps each day for four weeks before bladder cancer removal surgery can lower the chance of problems after the operation. About 146 adults with bladder cancer who are scheduled for surgery will take part. Half will be asked to i…

This study looks at whether placing a small tube (stent) in the urinary tract after bladder removal surgery affects recovery. About 70 adults with bladder or pelvic cancers will be randomly assigned to get a stent or not. The main goal is to see if avoiding stents lowers the risk…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study tests whether a blood test that looks for tumor DNA can detect if bladder cancer has come back after treatment. Researchers will collect blood, urine, and tissue samples from 100 people with muscle-invasive bladder cancer to see how well the test matches standard metho…

This study is testing whether a blood test can find tiny pieces of tumor DNA in people with muscle-invasive bladder cancer or upper tract urothelial cancer. Researchers will compare DNA from tumor tissue with DNA in blood samples taken during routine care. The goal is to see how …

This study is a large registry that will follow nearly 2,000 people with advanced kidney or bladder cancer in Germany. Researchers will collect information on the treatments patients actually receive, how well they work, and patients' quality of life. The goal is to understand re…

This study looks at how the drug enfortumab vedotin affects nerves in people with advanced or muscle-invasive bladder cancer. Researchers will use nerve tests and patient surveys to track changes over 9-15 weeks. The goal is to better understand and potentially reduce nerve damag…

This study looks at nerve damage (peripheral neuropathy) in people with advanced bladder cancer who are getting a combination of two drugs, pembrolizumab and enfortumab vedotin, as their first treatment. About 80 participants will be followed for a year to see how often nerve pro…

This study is testing a new way to choose chemotherapy for muscle-invasive bladder cancer. Doctors will grow a miniature version of a patient's tumor in the lab (called an organoid) and test different drugs on it to see which works best. Then, the patient receives the drug that k…

This study aims to understand the sexual health challenges faced by bladder cancer patients and develop a support program tailored to their needs. Researchers will interview 30 patients to learn about their experiences and preferences for professional help. The goal is to create …

This study collects blood and leftover tissue samples from 9,600 people with various cancers, including breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for cancer DNA in the blood. The goal is to better detect if cancer returns o…

This trial is investigating whether chemotherapy given before bladder removal surgery affects how accurate MRI scans are at staging muscle-invasive bladder cancer. Researchers will compare MRI results with actual tumor findings after surgery in 76 participants who either received…